一项在既往未经治疗的慢性淋巴细胞白血病成人患者中比较索罗托克拉(BGB-11417)联合赞布替尼(BGB-3111)与维奈托克联合阿卡替尼的研究
一项比较Sonrotoclax(BGB-11417)联合Zanubrutinib(BGB-3111)与Venetoclax联合Acalabrutinib治疗初治慢性淋巴细胞白血病患者的3期、开放标签、随机研究
The purpose of this study is to investigate the efficacy and safety of fixed-duration sonrotoclax (also known as BGB-11417) plus zanubrutinib (also known as BGB-3111) (SZ) compared with fixed-duration of venetoclax plus acalabrutinib (AV) in participants with previously untreated chronic lymphocytic leukemia (CLL).
研究概览
研究类型
注册 (估计的)
阶段
- 第三阶段
联系人和位置
学习联系方式
- 姓名:Study Director
- 电话号码:8778285568
- 邮箱:clinicaltrials@beonemed.com
学习地点
-
-
Beijing Municipality
-
Beijing、Beijing Municipality、中国、100730
- 招聘中
- Peking Union Medical College Hospital
-
-
Chongqing Municipality
-
Chongqing、Chongqing Municipality、中国、630014
- 招聘中
- The First Affiliated Hospital of Chongqing Medical University
-
-
Fujian
-
Fuzhou、Fujian、中国、350005
- 招聘中
- The First Affiliated Hospital of Fujian Medical University
-
-
Guangdong
-
Guangzhou、Guangdong、中国、510555
- 招聘中
- Sun Yat Sen University Cancer Center Huangpu Branch
-
Guangzhou、Guangdong、中国、510000
- 主动,不招人
- Zhujiang Hospital of Southern Medical University
-
-
Guangxi
-
Nanning、Guangxi、中国、530021
- 招聘中
- The First Affiliated Hospital of Guangxi Medical University
-
-
Guizhou
-
Guiyang、Guizhou、中国、550002
- 招聘中
- Guizhou Provincial Peoples Hospital
-
-
Heilongjiang
-
Harbin、Heilongjiang、中国、150000
- 招聘中
- Harbin Medical University Cancer Hospital
-
-
Henan
-
Zhengzhou、Henan、中国、450000
- 招聘中
- Henan Cancer Hospital
-
-
Hunan
-
Changsha、Hunan、中国、410011
- 招聘中
- The Second Xiangya Hospital of Central South University
-
-
Jiangsu
-
Nanjing、Jiangsu、中国、210029
- 招聘中
- Jiangsu Province Hospital
-
Nantong、Jiangsu、中国、201203
- 招聘中
- Affiliated Hospital of Nantong University
-
-
Jiangxi
-
Nanchang、Jiangxi、中国、330006
- 招聘中
- The Second Affiliated Hospital of Nanchang University
-
-
Shaanxi
-
Xi'an、Shaanxi、中国、710004
- 招聘中
- The Second Affiliated Hospital of Xian Jiaotong University
-
-
Shandong
-
Jinan、Shandong、中国、250000
- 招聘中
- Shandong Provincial Hospital
-
-
Shanghai Municipality
-
Shanghai、Shanghai Municipality、中国、200025
- 招聘中
- Rui Jin Hospital Shanghai Jiao Tong University School of Medicine
-
-
Sichuan
-
Chengdu、Sichuan、中国、610071
- 招聘中
- Sichuan Academy of Medical Sciences and Sichuan Provincial Peoples Hospital
-
-
Tianjin Municipality
-
Tianjin、Tianjin Municipality、中国、300020
- 招聘中
- Institute of Hematology and Hospital of Blood Disease
-
-
Yunnan
-
Kunming、Yunnan、中国、650032
- 招聘中
- First Affiliated Hospital of Kunming Medical University
-
-
Zhejiang
-
Hangzhou、Zhejiang、中国、310002
- 招聘中
- The First Affiliated Hospital, Zhejiang University School of Medicinechengzhan
-
-
-
-
British Columbia
-
Victoria、British Columbia、加拿大、V8R 6V5
- 招聘中
- Bc Cancer Victoria
-
-
Ontario
-
Hamilton、Ontario、加拿大、L8V 5C2
- 招聘中
- Juravinski Cancer Centre
-
-
Quebec
-
Montreal、Quebec、加拿大、QC H3t 1E2
- 招聘中
- Jewish General Hospital
-
Montreal、Quebec、加拿大、H4J 1C5
- 招聘中
- Ciusss Nim Hscm
-
Québec、Quebec、加拿大、G1J 1Z4
- 招聘中
- Chu de Quebec Universite Laval, Hopital de Lenfant Jesus, Centre Integre de Cancerologie (Cic)
-
Sherbrooke、Quebec、加拿大、J1H 5N4
- 招聘中
- Ciusss de Lestrie Chus
-
-
-
-
-
Brasília、巴西、70390140
- 招聘中
- Instituto Dor de Pesquisa E Ensino Distrito Federal
-
Porto Alegre、巴西、90110-270
- 招聘中
- Centro Gaucho Integrado de Oncologia Hospital Mae de Deus
-
Salvador、巴西、41950-640
- 招聘中
- Ensino E Terapia de Inovacao Clinica Amo Etica
-
São Paulo、巴西、05652-900
- 招聘中
- Sociedade Beneficente Israelita Brasileira Hospital Albert Einstein
-
São Paulo、巴西、01401-004
- 招聘中
- Instituto Dor de Pesquisa E Ensino Sao Paulo
-
-
-
-
-
Deggendorf、德国、94469
- 招聘中
- Donauisar Klinikum Deggendorf Klinik Fur Onkologie Und Hamatologie
-
Frankfurt am Main、德国、60389
- 招聘中
- Centrum Fur Haematologie Und Onkologie Bethanien
-
Münster、德国、48153
- 招聘中
- Geho Munster
-
Straubing、德国、94315
- 招聘中
- Klinikum St Elisabeth Straubing Gmbh Mvz Klinikum Straubing Gmbh
-
-
-
-
-
Bologna、意大利、40138
- 招聘中
- Irccs Azienda Ospedaliero Universitaria Bologna
-
Florence、意大利、50134
- 招聘中
- Aou Careggi, Servizio Sanitario Toscana
-
Milan、意大利、20132
- 招聘中
- Ospedale San Raffaele
-
Milan、意大利、20162
- 招聘中
- Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda
-
Padova、意大利、35128
- 招聘中
- Azienda Ospedaliera Di Padova
-
Roma、意大利、00168
- 招聘中
- Fondazione Policlinico Universitario Agostino Gemelli
-
-
-
-
-
Brno、捷克语、625 00
- 招聘中
- Fakultni Nemocnice Brno
-
Hradec Králové、捷克语、500 03
- 招聘中
- Fakultni Nemocnice Hradec Kralove
-
Olomouc、捷克语、77900
- 招聘中
- Fakultni Nemocnice Olomouc
-
Ostrava、捷克语、708 00
- 招聘中
- Fakultni Nemocnice Ostrava
-
PLZE、捷克语、323 00
- 招聘中
- Fakultni Nemocnice Plzen
-
Prague、捷克语、10000
- 招聘中
- Vseobecna Fakultni Nemocnice V Praze
-
-
-
-
-
Auckland、新西兰、1023
- 招聘中
- Auckland City Hospital
-
Auckland、新西兰、0622
- 招聘中
- North Shore Hospital
-
Christchurch、新西兰、8011
- 招聘中
- Health New Zealand Canterbury
-
Dunedin、新西兰、9016
- 招聘中
- Dunedin Hospital
-
Wellington、新西兰、6021
- 招聘中
- Wellington Regional Hospital (Ccdhb)
-
-
-
-
-
Bordeaux、法国、33076
- 招聘中
- Centre de Lutte Contre Le Cancer Institut Bergonie
-
ClermontFerrand、法国、63100
- 招聘中
- Chu Clermont Ferrand Therapie Cellulaire and Hematolo
-
Le Mans、法国、72037
- 招聘中
- Centre Hospitalier Le Mans
-
Lille、法国、59000
- 招聘中
- Hopital Claude Huriez Chu Lille
-
Lyon、法国、69373
- 招聘中
- Centre Leon Berard
-
Montpellier、法国、34090
- 招聘中
- Chu Montpellier Hopital Saint Eloi
-
Toulouse、法国、31100
- 招聘中
- Iuc Toulouse Oncopole
-
-
-
-
-
Brzozów、波兰、36-200
- 招聘中
- Szpital Specjalist W Brzozowie,Podkarpacki Osrodek Onkologiczny
-
Katowice、波兰、40-519
- 招聘中
- Pratia Onkologia Katowice
-
Krakow、波兰、30-727
- 招聘中
- Pratia McM Krakow
-
Lublin、波兰、20-090
- 招聘中
- Uniwersytecki Szpital Kliniczny Nr 4 W Lublinie
-
Wroclaw、波兰、50-367
- 招聘中
- Uniwersytecki Szpital Kliniczny Im Jana Mikulicza Radeckiego We Wroclawiu
-
-
-
-
New South Wales
-
Blacktown、New South Wales、澳大利亚、NSW 2148
- 招聘中
- Blacktown Cancer and Haematology Centre
-
Concord、New South Wales、澳大利亚、NSW 2139
- 招聘中
- Concord Repatriation General Hospital
-
St Leonards、New South Wales、澳大利亚、NSW 2065
- 招聘中
- Genesiscare North Shore
-
-
Queensland
-
Woolloongabba、Queensland、澳大利亚、QLD 4102
- 招聘中
- Princess Alexandra Hospital
-
-
Victoria
-
Clayton、Victoria、澳大利亚、VIC 3168
- 招聘中
- Monash Health
-
Heidelberg、Victoria、澳大利亚、VIC 3084
- 招聘中
- Austin Health
-
Malvern、Victoria、澳大利亚、VIC 3144
- 招聘中
- Cabrini Hospital Malvern
-
Melbourne、Victoria、澳大利亚、VIC 3004
- 招聘中
- The Alfred Hospital
-
-
-
-
-
Stockholm、瑞典、171 76
- 招聘中
- Karolinska Universitetssjukhuset Solna
-
-
-
-
-
Bucharest、罗马尼亚、30171
- 招聘中
- Coltea Clinical Hospital
-
Bucureti、罗马尼亚、022328
- 招聘中
- Institutul Clinic Fundeni
-
ClujNapoca、罗马尼亚、400015
- 招聘中
- Institutul Oncologic Prof Dr Ion Chiricuta Cluj Napoca
-
-
-
-
California
-
Duarte、California、美国、91010-3012
- 招聘中
- City of Hope National Medical Center
-
Orange、California、美国、92868-3201
- 招聘中
- Chao Family Comprehensive Cancer Center
-
Palo Alto、California、美国、94304-2205
- 招聘中
- Stanford Cancer Institute
-
-
Colorado
-
Aurora、Colorado、美国、80012-5405
- 招聘中
- Rocky Mountain Cancer Centers (Williams) Usor
-
-
Florida
-
Jacksonville、Florida、美国、32224-1865
- 招聘中
- Mayo Clinic Jacksonville
-
Miami、Florida、美国、33140
- 招聘中
- Mount Sinai Medical Center Braman Comprehensive Cancer Center
-
Tampa、Florida、美国、33612-9496
- 招聘中
- Moffitt Cancer Center
-
-
Illinois
-
Chicago、Illinois、美国、60611
- 招聘中
- Northwestern University
-
Zion、Illinois、美国、60099-2676
- 招聘中
- Midwestern Regional Medical Center
-
-
Louisiana
-
New Orleans、Louisiana、美国、70121-2429
- 招聘中
- Ochsner Clinic Foundation
-
-
Massachusetts
-
Boston、Massachusetts、美国、02215-5418
- 招聘中
- Dana Farber Cancer Institute
-
-
Minnesota
-
Rochester、Minnesota、美国、55905-0001
- 招聘中
- Mayo Clinic Rochester
-
-
Nebraska
-
Omaha、Nebraska、美国、68198
- 招聘中
- University of Nebraska Medical Center
-
-
New York
-
New York、New York、美国、10032
- 招聘中
- Columbia University Medical Center
-
-
North Carolina
-
Charlotte、North Carolina、美国、28204-2990
- 招聘中
- Atrium Health Levine Cancer Institute (Lci)
-
Durham、North Carolina、美国、27705-3976
- 招聘中
- Duke University Medical Center
-
-
Oregon
-
Eugene、Oregon、美国、97401
- 招聘中
- Oncology Associates of Oregon Willamette Valley Cancer Center
-
-
Pennsylvania
-
Pittsburgh、Pennsylvania、美国、15232-1309
- 招聘中
- Upmc Hillman Cancer Center(Univ of Pittsburgh)
-
-
Texas
-
Tyler、Texas、美国、75702-7522
- 招聘中
- Texas Oncology Tyler
-
-
Utah
-
Salt Lake City、Utah、美国、84112-5550
- 招聘中
- Huntsman Cancer Institute
-
-
Washington
-
Seattle、Washington、美国、98109-4433
- 招聘中
- Fred Hutchinson Cancer Research Center
-
-
Wisconsin
-
Milwaukee、Wisconsin、美国、53226-3522
- 招聘中
- Medical College of Wisconsin
-
-
-
-
-
Birmingham、英国、B15 2TH
- 招聘中
- Queen Elizabeth Hospital
-
Bournemouth、英国、BH7 7DW
- 招聘中
- University Hospitals Dorset Royal Bournemouth Hospital
-
Leeds、英国、LS9 7TF
- 招聘中
- St Jamess University Hospital
-
London、英国、SE5 9RS
- 招聘中
- Kings College Hospital
-
Norwich、英国、NR4 7UY
- 招聘中
- Norfolk and Norwich University Hospitals Nhs Foundation Trust
-
-
-
-
-
Almere Stad、荷兰、1315 RA
- 招聘中
- Flevoziekenhuis
-
Dordrecht、荷兰、3318 AT
- 招聘中
- Albert Schweitzer Ziekenhuis
-
Sgravenhage、荷兰、2545 AA
- 招聘中
- Hagaziekenhuis
-
-
-
-
-
Granada、西班牙、18014
- 招聘中
- Hospital Universitario Virgen de Las Nieves
-
Madrid、西班牙、28041
- 招聘中
- Hospital Universitario 12 de Octubre
-
Majadahonda、西班牙、28222
- 招聘中
- Hospital Universitario Puerta de Hierro Majadahonda
-
Murcia、西班牙、30120
- 招聘中
- Hospital Clinico Universitario Virgen de La Arrixaca
-
-
-
-
Gyeonggi-do
-
Seongnam-si、Gyeonggi-do、韩国、13620
- 招聘中
- Seoul National University Bundang Hospital
-
-
Seoul Teugbyeolsi
-
SeochoGu、Seoul Teugbyeolsi、韩国、06591
- 招聘中
- The Catholic University of Korea, Seoul St Marys Hospital
-
SeodaemunGu、Seoul Teugbyeolsi、韩国、03722
- 招聘中
- Severance Hospital Yonsei University Health System
-
Seoul、Seoul Teugbyeolsi、韩国、03080
- 招聘中
- Seoul National University Hospital
-
SongpaGu、Seoul Teugbyeolsi、韩国、05505
- 招聘中
- Asan Medical Center
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
- Treatment-naïve (TN) adults with confirmed diagnosis of CLL which requires treatment
- Eastern Cooperative Oncology Group (ECOG) score 0, 1, or 2
- Measurable disease by Computer Tomography/Magnetic Resonance Imaging
- Adequate bone marrow and organ function
Exclusion Criteria:
- Previous systemic treatment for CLL
- Known prolymphocytic leukemia or history of, or currently suspected, Richter's transformation
- Known central nervous system involvement
- History of confirmed progressive multifocal leukoencephalopathy (PML)
- Uncontrolled hypertension or clinically significant cardiovascular disease
Note: Other protocol defined Inclusion/Exclusion criteria may apply.
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:随机化
- 介入模型:并行分配
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:Arm A: Sonrotoclax plus Zanubrutinib
Participants will receive sonrotoclax and zanubrutinib for a fixed duration followed by observation. |
Administered orally.
其他名称:
Administered orally.
其他名称:
|
|
有源比较器:Arm B: Venetoclax plus Acalabrutinib
Participants will receive venetoclax and acalabrutinib for a fixed duration followed by observation. |
Administered orally.
其他名称:
Administered orally.
其他名称:
|
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Progression-Free Survival (PFS) as Determined by Independent Review Committee (IRC)
大体时间:Up to approximately 70 months
|
PFS is defined as the time from the date of randomization to the date of disease progression as determined by IRC or death due to any cause, whichever occurs first. |
Up to approximately 70 months
|
|
Rate of Undetectable Minimal Residual Disease at < 10^-4 sensitivity (uMRD4)
大体时间:Up to approximately 16 months
|
Rate of uMRD4 is defined as the percentage of participants that achieved uMRD4 measured in both peripheral blood (PB) and bone marrow aspirate (BMA) at the post-treatment follow-up visit (PTFU1) based on next generation sequencing (NGS). |
Up to approximately 16 months
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
PFS in High-Risk Participants
大体时间:Up to approximately 70 months
|
PFS is defined as the time from the date of randomization to the date of disease progression as determined by IRC or death due to any cause, whichever occurs first. |
Up to approximately 70 months
|
|
Overall Survival (OS)
大体时间:Up to approximately 70 months
|
OS is defined as the time from the date of randomization to the date of death due to any cause. |
Up to approximately 70 months
|
|
Overall Response Rate (ORR) as Determined by IRC
大体时间:Up to approximately 70 months
|
ORR is defined as the percentage of participants with a complete response (CR), complete response with incomplete hematopoietic recovery (CRi), nodal partial response (nPR), or partial response (PR), before disease progression, death, or the start of new anti-CLL treatment (whichever is earlier), as assessed by IRC. |
Up to approximately 70 months
|
|
Rate of Undetectable Minimal Residual Disease at < 10^-5 sensitivity (uMRD5)
大体时间:Up to approximately 16 months
|
Rate of uMRD5 is defined as the percentage of participants who achieved uMRD5 measured in both PB and BMA at the PTFU1 Visit based on NGS, before disease progression, death, or the start of new anti-CLL treatment (whichever is earlier). |
Up to approximately 16 months
|
|
Number of Participants with Adverse Events
大体时间:Up to approximately 70 months
|
Number of participants with treatment-emergent adverse events (TEAEs), adverse events of clinical interest, and serious adverse events (SAEs), including laboratory values, vital signs, and physical examination findings. |
Up to approximately 70 months
|
|
PFS Determined by Investigator Assessment
大体时间:Up to approximately 70 months
|
PFS is defined as the time from the date of randomization to the date of disease progression as determined by investigator or death due to any cause, whichever occurs first. |
Up to approximately 70 months
|
|
Complete Response Rate (CRR) by IRC and Investigator Assessment
大体时间:Up to approximately 70 months
|
CRR is defined as the percentage of participants with a CR or CRi before disease progression, death, or the start of new anti-CLL treatment (whichever is earlier). |
Up to approximately 70 months
|
|
ORR Determined by Investigator Assessment
大体时间:Up to approximately 70 months
|
ORR is defined as the percentage of participants with a complete response or partial response, before disease progression, death, or the start of new anti-CLL treatment (whichever is earlier), as assessed by investigator. |
Up to approximately 70 months
|
|
Duration of Response (DOR)
大体时间:Up to approximately 70 months
|
Duration of response (determined by both IRC and investigator assessment) is defined as the time from the first qualifying response (CR, CRi, nPR, or PR) until CLL progression or death. DOR analysis will only include responders. |
Up to approximately 70 months
|
|
Time to Next Treatment (TTNT)
大体时间:Up to approximately 70 months
|
TTNT is defined as the time from randomization to the start of the next treatment for CLL. |
Up to approximately 70 months
|
|
Change from Baseline in Score on European Organization for Research and Treatment of Cancer (EORTC) Item Library (IL)-409 Questionnaire
大体时间:At baseline and up to approximately 70 months
|
Patient-reported symptoms of global health status (GHS), role functioning, and physical functioning, symptom burden and physical condition/fatigue will be measured using the European Organization for Research and Treatment of Cancer quality of life questionnaire EORTC IL-409 (an itemized version of [EORTC] quality of life questionnaire core 30 [QLQ-C30] and its CLL module CLL17). The EORTC-IL-409 consists of 17 questions answered on a 4-point scale where 1 = Not at all (best) to 4 = Very Much (worst) and 2 global health questions answered on a 7-point scale where 1 = Very poor (worst) to 7 = Excellent (best). Higher scores in GHS and functional scales and lower scores in symptom scales indicate better quality of life. |
At baseline and up to approximately 70 months
|
合作者和调查者
调查人员
- 研究主任:Study Director、BeOne Medicines
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
其他相关的 MeSH 术语
其他研究编号
- BGB-11417-304
- 2025-524366-21-00 (克蒂斯)
- 2025 (美国 NIH 拨款/合同)
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
IPD 计划说明
BeOne shares data on completed studies responsibly and provides qualified scientific and medical researchers access to data and supporting documentation for clinical trials in dossiers for medicines and indications after submission and approval in the United States, China, and Europe. Clinical trials supporting subsequent local approvals, new indications, or combination products are eligible for sharing once corresponding regulatory approvals are achieved.
BeOne shares data only when permitted by applicable data privacy and security laws and regulations, when it is feasible to do so without compromising the privacy of study participants, and other considerations.
Qualified researchers with appropriate competencies who are engaged in novel scientific research may submit a request for participant-level data with a research proposal for BeOne review. Research teams must include a biostatistician and sign a Data Sharing Agreement prior to receiving access to clinical trial data.
IPD 共享时间框架
See plan description
IPD 共享访问标准
See plan description
IPD 共享支持信息类型
- 研究方案
- 树液
- 企业社会责任
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.